Filana Therapeutics
FLNA
26 hedge funds and large institutions have $9.31M invested in Filana Therapeutics in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 3 closing their positions.
0.68% less ownership
Funds ownership: 35.94% → 35.26% (-0.68%)
4% less capital invested
Capital invested by funds: $9.65M → $9.31M (-$344K)
7% less funds holding
Funds holding: 28 → 26 (-2)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$64.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$61.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.8K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.8K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$101K |
| 2 |
Renaissance Technologies
New York
|
-$67K |
| 3 |
GS
Gagnon Securities
New York
|
-$63K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$48.1K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$43K |
FLNA Hedge Fund Activity: Q4 2017 in Review
26 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q4 2017, worth a combined $9.31M — down 3.6% from $9.65M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FLNA and 1 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $64.1K. The largest seller was Bridgeway Capital Management, cutting an estimated $101K.
- 26 institutional investors held Filana Therapeutics (FLNA) as of Q4 2017, down from 28 in Q3 2017.
- Funds reported $9.31M of Filana Therapeutics stock for Q4 2017, down 3.6% quarter-over-quarter.
- 1 fund opened new Filana Therapeutics positions in Q4 2017 and 3 closed out, a net change of -2 holders.
- The largest Filana Therapeutics buyer in Q4 2017 was Virtu Financial, an estimated $64.1K added.
- The largest Filana Therapeutics seller in Q4 2017 was Bridgeway Capital Management, an estimated $101K sold.
Based on aggregated 13F filings for Q4 2017.